Compare Home Depot Inc (HD) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Sanofi SA — how do they compare? Home Depot Inc trades at $290.74 (market cap $294.79B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Home Depot Inc is far larger — about 3.1× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Sanofi SA for 94 Days on average.
| HD | SNY | |
|---|---|---|
Market Cap | $294.79B | $95.18B |
Volume | 8,693,917 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $52.34 |
52-Week Low | $281.15 | $39.51 |
Typical Hold Time | 139 Days | 94 Days |
Enterprise Value | $355.27B | $114.48B |
Dividend Yield | 3.15% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $295.47, up 3.39% with strong earnings beats in recent quarters. The stock shows bullish technical signals with support at $290 and resistance at $298. Fundamentally, HD maintains solid profitability with 8.41% net margin and 104.3% ROE, though revenue growth has moderated. Analyst consensus remains positive with 58.73% buy ratings and a $379.93 price target, representing 28.6% upside potential from current levels.
HD presents a compelling investment case with strong operational performance and analyst support, though faces headwinds from weakening housing demand and margin pressure. The stock's current valuation at 20.68 P/E appears reasonable given its market leadership position and consistent dividend payments, but investors should monitor housing market trends and competitive pressures.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
